N/A
Completed N=31
Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis
Source: ClinicalTrials.gov NCT02713711 ↗Enrolled (actual)
31
Serious AEs
—
Results posted
Feb 2021
Primary outcomePrimary: Percentage Change in Psoriatic Plaque Area — 108.22; 78.89; 84.29; 63.69 percentage change — p=0.3262
Summary
The purpose of this study is to compare the effectiveness of artificial balneotherapy (AB), phototherapy (PT) and artificial balneophototherapy (BPT) in the treatment of plaque psoriasis, evaluating the plaque area, alteration of skin pigmentation, Psoriasis Area and Severity Index (PASI) score determination and quality-of-life assessment by Short Form 36 Health Survey (SF-36) and Psoriasis Disability Index (PDI) scores during the month of treatment. Methods: Experimental study, prospective, randomized, single-blind. 14 subjects participated from the city of Talca, Chile medically diagnosed with psoriasis, more than one plaque in the skin without topical treatment voluntarily. All subjects completed the study that consisted of 12 sessions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change in Psoriatic Plaque Area |
108.22; 78.89; 84.29; 63.69; 101.26; 84.25 | 0.3262 |
| SECONDARY Arbitrary Units Change in Psoriatic Plaque Erythema |
172.1; 150.2; 163.9; 159.3; 179.4; 136.5 | 0.2080 |
| SECONDARY Number of Participants With Change in PASI From Baseline to Session 12 |
4; 7; 3 | — |
| SECONDARY Number of Participants With Change in Quality of Life |
13; 1 | — |
| SECONDARY Number of Participants With Change in Psoriasis Disability |
13; 1 | — |
Eligibility Criteria
Inclusion Criteria
- be more than 18 years-old,
- have more than one plaque on the skin,
- medically diagnosed as plaque psoriasis over a year ago and,
- without concurrent topical treatment for Psoriasis (by own choice).
Exclusion Criteria
- pregnancy,
- skin carcinoma,
- severe diabetes mellitus,
- uncontrolled chronic pathologies and/or severe cardiac/renal insufficiency and/or acute infections.
Data sourced from ClinicalTrials.gov (NCT02713711). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.